

## Polyclonal Anti-Vaccinia Virus (WR) F9L Protein, (antiserum, Rabbit)

**Catalog No. NR-630**

**For research use only. Not for human use.**

### Contributor:

Gary H. Cohen, Ph.D., Professor and Chair, Department of Microbiology, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania and Roselyn J. Eisenberg, Ph.D., Professor, Department of Pathobiology, Head, Laboratories of Microbiology and Immunology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

### Product Description:

Antiserum to the F9L membrane glycoprotein of the Western Reserve (WR) strain of vaccinia virus was produced by immunization of rabbits with a recombinant form of the F9L protein.<sup>1,2</sup> Recombinant F9L is available as BEI Resources NR-2626.

### Material Provided:

Each vial contains approximately 0.2 mL of rabbit polyclonal antiserum to the F9L protein of the Western Reserve (WR) strain of vaccinia virus.

### Packaging/Storage:

NR-630 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen and should be stored at -20°C or colder immediately upon arrival.

### Functional Activity:

NR-630 is specific to the F9L protein of vaccinia virus (WR) as determined by Western blot and ELISA.

### Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Polyclonal Anti-Vaccinia Virus (WR) F9L Protein, (antiserum, Rabbit), NR-630."

### Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 4th ed. Washington, DC: U.S. Government Printing Office, 1999. HHS Publication No. (CDC) 93-8395. This text is available online at [www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4toc.htm](http://www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4toc.htm).

### Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.beiresources.org](http://www.beiresources.org).

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

### Use Restrictions:

**This material is distributed for internal research, non-commercial purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to negotiate a license. U.S. Government contractors may need a license before first commercial sale.

### References:

1. Lustig, S., et al. "Combinations of Polyclonal or Monoclonal Antibodies to Proteins of the Outer Membranes of the Two Infectious Forms of Vaccinia Virus Protect Mice against a Lethal Respiratory Challenge." *J. Virol.* 79 (2005): 13454-13462. PubMed: 16227266.
2. Fogg, C., et al. "Protective Immunity to Vaccinia Virus Induced by Vaccination with Multiple Recombinant Outer Membrane Proteins of Intracellular and Extracellular Virions." *J. Virol.* 78 (2004): 10230-10237. PubMed: 15367588.

ATCC® is a trademark of the American Type Culture Collection.